JP2024520577A5 - - Google Patents
Info
- Publication number
- JP2024520577A5 JP2024520577A5 JP2023573662A JP2023573662A JP2024520577A5 JP 2024520577 A5 JP2024520577 A5 JP 2024520577A5 JP 2023573662 A JP2023573662 A JP 2023573662A JP 2023573662 A JP2023573662 A JP 2023573662A JP 2024520577 A5 JP2024520577 A5 JP 2024520577A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- nos
- acid sequences
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195470P | 2021-06-01 | 2021-06-01 | |
| US63/195,470 | 2021-06-01 | ||
| PCT/EP2022/064703 WO2022253805A1 (en) | 2021-06-01 | 2022-05-31 | Anti-nkg2a antibodies and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520577A JP2024520577A (ja) | 2024-05-24 |
| JP2024520577A5 true JP2024520577A5 (https=) | 2025-06-06 |
Family
ID=82117230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573662A Pending JP2024520577A (ja) | 2021-06-01 | 2022-05-31 | 抗ｎｋｇ２ａ抗体及び組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12012450B2 (https=) |
| EP (1) | EP4347651A1 (https=) |
| JP (1) | JP2024520577A (https=) |
| KR (1) | KR20240016991A (https=) |
| CN (1) | CN117460748A (https=) |
| AR (1) | AR126001A1 (https=) |
| AU (1) | AU2022286617A1 (https=) |
| BR (1) | BR112023024772A2 (https=) |
| CA (1) | CA3222040A1 (https=) |
| CL (1) | CL2023003562A1 (https=) |
| CO (1) | CO2023015982A2 (https=) |
| IL (1) | IL308695A (https=) |
| MX (1) | MX2023014320A (https=) |
| PE (1) | PE20240372A1 (https=) |
| PH (1) | PH12023553123A1 (https=) |
| TW (1) | TW202313683A (https=) |
| WO (1) | WO2022253805A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024140820A1 (zh) * | 2022-12-28 | 2024-07-04 | 浙江博锐生物制药有限公司 | 抗nkg2a抗体及其用途 |
| WO2024260280A1 (en) * | 2023-06-21 | 2024-12-26 | Elpiscience (Suzhou) Biopharma, Ltd. | Antibodies or antigen-binding fragments binding to nkg2a and uses thereof |
| CN121941711A (zh) * | 2024-02-08 | 2026-04-28 | 翰思艾泰生物医药科技(武汉)股份有限公司 | Nkg2a/cd94靶向抗体及其用途 |
| CN121108342B (zh) * | 2025-09-08 | 2026-03-03 | 北京明璨生物科技有限公司 | 包含抗体和nk细胞的组合物在治疗癌症中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| KR20100110864A (ko) * | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| US10329348B2 (en) * | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| PH12018502112B1 (en) | 2016-04-12 | 2024-03-27 | Servier Lab | Anti-tim-3 antibodies and compositions |
| US12534526B2 (en) | 2018-11-07 | 2026-01-27 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A antibody, preparation method therefor and application thereof |
| CN113316590B (zh) * | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
-
2022
- 2022-05-31 WO PCT/EP2022/064703 patent/WO2022253805A1/en not_active Ceased
- 2022-05-31 EP EP22732067.8A patent/EP4347651A1/en active Pending
- 2022-05-31 MX MX2023014320A patent/MX2023014320A/es unknown
- 2022-05-31 AR ARP220101426A patent/AR126001A1/es unknown
- 2022-05-31 PH PH1/2023/553123A patent/PH12023553123A1/en unknown
- 2022-05-31 TW TW111120182A patent/TW202313683A/zh unknown
- 2022-05-31 IL IL308695A patent/IL308695A/en unknown
- 2022-05-31 BR BR112023024772A patent/BR112023024772A2/pt unknown
- 2022-05-31 JP JP2023573662A patent/JP2024520577A/ja active Pending
- 2022-05-31 AU AU2022286617A patent/AU2022286617A1/en active Pending
- 2022-05-31 CA CA3222040A patent/CA3222040A1/en active Pending
- 2022-05-31 KR KR1020237043690A patent/KR20240016991A/ko active Pending
- 2022-05-31 PE PE2023003150A patent/PE20240372A1/es unknown
- 2022-05-31 US US17/828,740 patent/US12012450B2/en active Active
- 2022-05-31 CN CN202280039227.XA patent/CN117460748A/zh active Pending
-
2023
- 2023-11-23 CO CONC2023/0015982A patent/CO2023015982A2/es unknown
- 2023-11-29 CL CL2023003562A patent/CL2023003562A1/es unknown
-
2024
- 2024-05-13 US US18/661,970 patent/US20240294638A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520577A5 (https=) | ||
| JP2021511811A5 (https=) | ||
| CN115551888B (zh) | 抗cd73抗体及其用途 | |
| JP5723279B2 (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| JP2021514664A5 (https=) | ||
| JP2021524244A5 (https=) | ||
| JP2021534762A5 (https=) | ||
| JP2018529359A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| JP2021525546A5 (https=) | ||
| CN102939306B (zh) | 用于治疗癌症的人源化抗cxcr4抗体 | |
| JP2020510422A5 (https=) | ||
| HRP20211820T1 (hr) | Anti-tim-3 protutijela i pripravci | |
| JP2022527635A5 (https=) | ||
| JP2015508280A5 (https=) | ||
| JP2022527151A5 (https=) | ||
| TW201026325A (en) | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment | |
| JP2022548764A5 (https=) | ||
| JP2021528047A5 (https=) | ||
| CN101535344A (zh) | 新型抗增殖抗体 | |
| CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
| JP2023522630A5 (https=) | ||
| JP2022547416A5 (https=) | ||
| TW202221035A (zh) | 抗ilt2抗體及其用途 | |
| CN112094348B (zh) | 抗人Tim3抗体或其功能性片段及其应用 |